EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Substitution of Chronic Insulin Therapy with Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Co-transporter-2 Inhibitors

Hideshi Okada, Genzou Takemura, Kodai Suzuki, Nagisa Miyazaki, Eiji Kuroda, Yoko Ito, Toshihiko Chikaishi, Hiroaki Ushikoshi, Shinji Ogura

Diabetes Research - Open Journal · 2015

DOI: 10.17140/droj-1-113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Research - Open Journal, 2015. Verfasst von Hideshi Okada und 8 weiteren Autor:innen. Die Arbeit nennt 1 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Insulin is a very useful and widely used treatment for diabetes. Temporary insulin therapy improves glucose toxicity due to improved β-cell function of the pancreas. Upon achieving glycemic control, insulin treatment could be discontinued and substituted with oral hypoglycemic agents. Nevertheless, insulin therapy is associated with side effects such as hypoglycemia, allergic reactions, and angioneurotic edema. Over this past decade, there have been rapid advances in diabetes treatment, including the introduction of Dipeptidyl peptidase-4 (DPP-4) inhibitors and Sodium-glucose cotransporter-2 (SGLT2) inhibitors. We present here the caseof a patient with type 2 diabetes who discontinued insulin therapy after more than 20 years by switching to oral hypoglycemic agents including a DPP-4 inhibitor and a SGLT2 inhibitor. A 64-year-old man with type 2 diabetes was being treated with Lispro Mix 50 insulintwice daily. He was started on subcutaneous insulin 20 years ago. He also has hypertension and hyperlipidemia, and visits the home clinic once a month. He consulted the clinic because he strongly wanted to discontinue insulin therapy due to his work situation. At the time, he was taking Lispro Mix 50 insulin twice daily (morning: 10U, evening: 6U) and his HbA1c was 7.3%. His body weight was 47.0 kg, height was 160 cm, and body mass index was 18.4 kg/ m2. His blood pressure was 118/68 mm Hg and his pulse rate was 72 beats per minute. After evaluation of his condition, insulin therapy was discontinued and oral therapy consisting of glimepiride 1 mg/day, teneligliptin 20 mg/day, and canagliflozin 100 mg/day was started. Serum C-peptide and HbA1c were 0.9 ng/ml and 7.3% respectively three months later.

Zitieren

APA

Okada, H., Takemura, G., Suzuki, K., Miyazaki, N., Kuroda, E., Ito, Y., Chikaishi, T., Ushikoshi, H., & Ogura, S. (2015). Substitution of Chronic Insulin Therapy with Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Co-transporter-2 Inhibitors. Diabetes Research - Open Journal. https://doi.org/10.17140/droj-1-113

Vancouver

Okada H, Takemura G, Suzuki K, Miyazaki N, Kuroda E, Ito Y, et al. Substitution of Chronic Insulin Therapy with Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Co-transporter-2 Inhibitors. Diabetes Research - Open Journal. 2015. doi:10.17140/droj-1-113

BibTeX
@article{Okada2015,
  author = {Okada, Hideshi and Takemura, Genzou and Suzuki, Kodai and Miyazaki, Nagisa and Kuroda, Eiji and Ito, Yoko and Chikaishi, Toshihiko and Ushikoshi, Hiroaki and Ogura, Shinji},
  title = {Substitution of Chronic Insulin Therapy with Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Co-transporter-2 Inhibitors},
  journal = {Diabetes Research - Open Journal},
  year = {2015},
  doi = {10.17140/droj-1-113}
}
Kostenlos starten →